Epoprostenol for the treatment of pulmonary arterial hypertension

References

• Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1):S20–31. .
   PubMed Web of Science ®Google Scholar
• Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655–1665.
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336(2):111–117.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349. .
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301. .
   PubMed Web of Science ®Google Scholar
• Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1802004. .
   PubMed Web of Science ®Google Scholar
• Spaczyńska M, Rocha SF, Oliver E. Pharmacology of pulmonary arterial hypertension: an overview of current and emerging therapies. ACS Pharmacol Transl Sci. 2020;3(4):598–612.
   PubMedGoogle Scholar
• Farber HW, Miller DP, Meltzer LA, et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL registry. J Heart Lung Transplant. 2013;50(2):1114–1122. .
   Google Scholar
• Quezada Loaiza CA, Velázquez Martín MT, Jiménez López-Guarch C, et al. La evolución de la hipertensión arterial pulmonar a lo largo de 30 años: experiencia de un centro de referencia. Rev Española Cardiol (Engl Ed). 2017;70(11):915–923.
   PubMedGoogle Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. .
   PubMed Web of Science ®Google Scholar
• Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563–645.
   PubMed Web of Science ®Google Scholar
• Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1):1801887. .
   PubMed Web of Science ®Google Scholar
• Huertas A, Guignabert C, Barberà JA, et al. Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: highlights from basic research to therapy. Eur Respir J. 2018;51(4):1700745. .
   PubMed Web of Science ®Google Scholar
• Abe K, Shinoda M, Tanaka M, et al. Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension. Cardiovasc Res. 2016;111(1):16–25. .
   PubMed Web of Science ®Google Scholar
• Dai Z, Li M, Wharton J, et al. Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2α. Circulation. 2016;133(24):2447–2458. .
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99(7):675–691.
   PubMed Web of Science ®Google Scholar
• Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122(9):920–927. .
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al., 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 37(1): 67–119. 2016. .
   PubMed Web of Science ®Google Scholar
• Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175–4181. .
   PubMed Web of Science ®Google Scholar
• Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. . Internet
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111. .
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–1436.
   PubMed Web of Science ®Google Scholar
• Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med. 2017;11(6):491–503.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2):487–492.
   PubMed Web of Science ®Google Scholar
• Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–2086.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016;47(6):1727–1736.
   PubMed Web of Science ®Google Scholar
• Hoeper MM. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26(5):858–863.
   PubMed Web of Science ®Google Scholar
• Galiè N, Negro L, Simonneau G. The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev. 2009;18(113):148–153.
   PubMedGoogle Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818. .
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533. .
   PubMed Web of Science ®Google Scholar
• Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–844.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–456. .
   PubMed Web of Science ®Google Scholar
• Swinnen K, Quarck R, Godinas L, et al. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. 2019;28(154).Eur Respir Rev an Off J Eur Respir Soc
   Google Scholar
• Del Pozo R, Blanco I, Hernández-González I, et al. Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: insights from the Spanish REHAP registry. Int J Cardiol. 2019;275:158–164.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112(7):485–491.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–434.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165(6):800–804.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–1922.
   PubMed Web of Science ®Google Scholar
• White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707–717.
   PubMed Web of Science ®Google Scholar
• López-Medrano F, Fernández-Ruiz M, Ruiz-Cano MJ, et al. Alta incidencia de bacteriemia por bacilos gramnegativos en pacientes con hipertensión pulmonar tratados con treprostinil por vía intravenosa. Arch Bronconeumol. 2012;48(12):443–447.
   PubMedGoogle Scholar
• Nicolas LB, Krause A, Gutierrez MM, et al. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. Br J Clin Pharmacol. 2012;74(6):978–989.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Delcroix M, Bergot E, et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J. 2014;167(2):210–217.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Noordegraaf AV. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. Eur Respir Rev. 2017;26(143):160055.
   PubMed Web of Science ®Google Scholar
• Akagi S, Nakamura K, Miyaji K, et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J. 2010;74(10):2200–2205.
   PubMed Web of Science ®Google Scholar
• Akagi S, Matsubara H, Nakamura K, et al. Marked reduction of pulmonary artery pressure after registration for lung transplantation is associated with long-term survival in patients with pulmonary arterial hypertension – Cohort study. Circ J. 2020;84(2):245–251. .
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–1482.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–788. .
   PubMed Web of Science ®Google Scholar
• Bergot E, Sitbon O, Cottin V, et al. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. Int J Cardiol. 2014;172(3):561–567.
   PubMed Web of Science ®Google Scholar
• Ogawa A, Ejiri K, Matsubara H. Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci. 2014;118(2):414–419.
   PubMed Web of Science ®Google Scholar
• Tokunaga N, Ogawa A, Ito H, et al. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J Cardiol. 2016;68(6):542–547.
   PubMed Web of Science ®Google Scholar
• Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997;30(2):343–349.
   PubMed Web of Science ®Google Scholar
• Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91(5):632–635. .
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99(14):1858–1865.
   PubMed Web of Science ®Google Scholar
• Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003;167(4):580–586. .
   PubMed Web of Science ®Google Scholar
• Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162(5):1846–1850.
   PubMed Web of Science ®Google Scholar
• Rafanan AL, Maurer J, Mehta AC, et al. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest. 2000;118(5):1497–1500.
   PubMedGoogle Scholar
• Fix OK, Bass NM, De Morco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transplant. 2007;13(6):875–885.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Frantz RP, Mcgoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatol. 1999;30(3):641–648.
   PubMed Web of Science ®Google Scholar
• Mclaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999;130(9):740–743.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–359.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Jaïs X, Savale L, et al., Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 43(6): 1691–1697. 2014.
   PubMed Web of Science ®Google Scholar
• Boucly A, Savale L, Weatherald JC et al. Impact of initial triple combination therapy on long-term survival in Pulmonary Arterial Hypertension (PAH). [abstract]. Mini Symposium in American Thoracic Society 2019 International Conference. Dallas, TX, USA. Available from: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5585
   Google Scholar
• McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8–18.
   PubMedGoogle Scholar
• Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019;53(1):1801906.
   PubMed Web of Science ®Google Scholar
• Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec;25(142):431–437.
   PubMed Web of Science ®Google Scholar
• Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2016;47(5):1518-1534.
   Google Scholar
• Navas Tejedor P, Palomino Doza J, Tenorio Castaño JA, et al. Expresividad variable de una mutación fundadora en el gen EIF2AK4 en pacientes con enfermedad venooclusiva pulmonar hereditaria. Impacto en la supervivencia. Rev Esp Cardiol (Engl Ed). 2018;54(1):86–94.
   Google Scholar
• Ivy DD, Calderbank M, Wagner BD, et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol. 2009;30(9):823–829.
   PubMed Web of Science ®Google Scholar
• Demerouti E, Karyofyllis P, Manginas A, et al. Improving survival in patients with pulmonary arterial hypertension: focus on intravenous epoprostenol. Am J Cardiovasc Drugs. 2019;19(2):99–105.
   PubMed Web of Science ®Google Scholar
• Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007;132(3):757–763.
   PubMed Web of Science ®Google Scholar
• Holthaus N, Prins K, Rose L, et al. EXPRESS: transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients. Pulm Circ. 2019;9(3):2045894019862167.
   Web of Science ®Google Scholar